文献速递细菌感染、耐药与抗菌药物艾滋病与性传播感染

中国无并发症淋病广泛使用高剂量头孢曲松治疗且无治疗失败报告:5年多中心监测数据

Widespread Use of High-dose Ceftriaxone Therapy for Uncomplicated Gonorrhea Without Reported Ceftriaxone Treatment Failure: Results From 5 Years of Multicenter Surveillance Data in China.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该研究基于2013—2017年中国5省7家医院的多中心监测网络,纳入1686例淋球菌感染患者,分析抗生素处方模式及疗效。结果显示,头孢曲松敏感性下降菌株占9.8%(131/1333),83.1%患者首选头孢曲松注射,其中72.7%(1018/1401)使用>1000 mg剂量;所有患者均治愈,无论菌株敏感性或剂量如何。结论为中国无头孢曲松治疗无并发症淋病失败报告,但高剂量头孢曲松广泛使用,其影响需进一步研究。

要点

  • 头孢曲松敏感性下降淋球菌占9.8%(131/1333),波动于5.6%—12.1%。
  • 83.1%患者首选头孢曲松注射,72.7%(1018/1401)使用>1000 mg剂量。
  • 所有患者均治愈,无头孢曲松治疗失败报告。

核心结论

  • 中国无头孢曲松治疗无并发症淋病失败报告,但高剂量头孢曲松广泛使用,其影响需进一步研究。

研究设计与样本

  • 基于2013年1月1日至2017年12月31日中国5省7家医院多中心监测网络的随访数据,纳入1686例淋球菌感染患者,采用多项逻辑回归分析人口学/临床变量与头孢曲松敏感性及高剂量处方的关联。

主要发现

  • 头孢曲松敏感性下降菌株占9.8%(131/1333),波动于5.6%—12.1%。
  • 83.1%患者首选头孢曲松注射,其中72.7%(1018/1401)使用>1000 mg剂量。
  • 既往淋病或其他性传播感染史(AOR 1.618,95%CI 1.11—2.358;AOR 2.08,95%CI 1.41—3.069)及已使用抗生素(AOR 1.599,95%CI 1.041—2.454)与更高头孢曲松处方剂量相关。
  • 所有患者均治愈,无论菌株对头孢曲松敏感性或所接受剂量如何。

临床怎么用

  • 中国无并发症淋病治疗中头孢曲松普遍使用高剂量(>1000 mg),但所有患者均治愈,临床可参考此实践背景。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antimicrobial resistance to Neisseria gonorrhoeae has emerged for each of the antibiotics recommended as first-line therapies following their introduction into clinical practice. To improve rational and effective clinical antibiotic treatment, we analyzed the prescription patterns of antibiotics and their therapeutic effect in the treatment of uncomplicated gonorrhea in China. METHODS: We obtained data from a follow-up multicenter surveillance program. Multinomial logistic regression analyses were conducted to explore the associations between demographic/clinical variables with the levels of sensitivity to ceftriaxone and prescription of high-dose ceftriaxone. RESULTS: In this study, 1686 patients infected with N. gonorrhoeae were recruited in a surveillance network during 1 January 2013 through 31 December 2017 in 7 hospitals distributed in 5 provinces. The prevalence of isolates with decreased susceptibility to ceftriaxone was 9.8% (131/1333), fluctuating between 5.6% and 12.1%. Injectable ceftriaxone was chosen as the first-line treatment among 83.1% of patients, and most of them (72.7% [1018/1401]) received >1000 mg dosage. Patients who were previously infected with gonorrhea or other sexually transmitted infections (adjusted odds ratio [AOR], 1.618 [95% confidence interval {CI}, 1.11-2.358]; AOR, 2.08 [95% CI, 1.41-3.069]) or who already used antibiotics for this infection (AOR, 1.599 [95% CI, 1.041-2.454]) were associated with a higher prescribed ceftriaxone dosage. All of the patients recruited in this study were cured regardless of the isolates' susceptibility to ceftriaxone or the dosage of ceftriaxone they received. CONCLUSIONS: No ceftriaxone treatment failure for uncomplicated gonorrhea was reported in China; however, high-dose ceftriaxone was widely used in China. Its impacts need further study.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Han Y, Yin Y, Dai X, et al. Widespread Use of High-dose Ceftriaxone Therapy for Uncomplicated Gonorrhea Without Reported Ceftriaxone Treatment Failure: Results From 5 Years of Multicenter Surveillance Data in China. Clin Infect Dis. 2020. PMID: 30838398. doi:10.1093/cid/ciz170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。